(MDXG) MiMedx - Performance 3.1% in 12m
Compare MDXG with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
31.58%
#22 in Group
Rel. Strength
29.41%
#5617 in Universe
Total Return 12m
3.06%
#62 in Group
Total Return 5y
105.54%
#25 in Group
P/E 24.6
59th Percentile in Group
P/E Forward 19.5
69th Percentile in Group
PEG 2.97
88th Percentile in Group
FCF Yield 7.37%
89th Percentile in Group
12m Total Return: MDXG (3.1%) vs XBI (-12.3%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
10.1% | 18% | 166% | 12.1 | 11 | 1.43 | 74.6% | 16.1% |
HLN NYSE Haleon |
14.3% | 31.2% | 47% | 24.4 | 20.2 | 1.79 | 69.1% | 13.6% |
AMGN NASDAQ Amgen |
-2.93% | -8.78% | 30.7% | 25.5 | 13.5 | 0.95 | 0.60% | 41% |
LONN SW Lonza |
9.55% | 9.34% | 30.4% | 67.1 | 35.1 | 1.28 | 2.20% | -12.5% |
BIM PA Biomerieux |
0.78% | 17.8% | -2.14% | 32.5 | 25.2 | 1.52 | -38.5% | -25.1% |
KMDA NASDAQ Kamada |
21.4% | 25.3% | -4.13% | 26.6 | 23.9 | 0.96 | 32.5% | 3.93% |
NBIX NASDAQ Neurocrine Biosciences |
34.3% | -15.5% | 3.48% | 32.3 | 21.6 | 0.27 | 68.0% | 31.9% |
ERF PA Eurofins Scientific SE |
20.4% | -0.39% | 7.63% | 26.6 | 13.6 | 0.56 | -66.6% | -17.1% |
Performance Comparison: MDXG vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for MDXG
Total Return (including Dividends) | MDXG | XBI | S&P 500 |
---|---|---|---|
1 Month | 8.16% | 11.81% | 13.81% |
3 Months | -11.14% | -13.61% | -6.30% |
12 Months | 3.06% | -12.29% | 10.65% |
5 Years | 105.54% | -24.89% | 107.77% |
Trend Score (consistency of price movement) | MDXG | XBI | S&P 500 |
1 Month | -7.00% | 72.9% | 83% |
3 Months | -89.6% | -83% | -75.3% |
12 Months | 32.0% | -51.6% | 50.1% |
5 Years | 7.80% | -53.9% | 84.1% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #186 | -3.26% | -4.96% |
3 Month | #125 | 2.86% | -5.17% |
12 Month | #63 | 17.5% | -6.86% |
5 Years | #26 | 174% | -1.07% |
FAQs
Does MDXG MiMedx outperforms the market?
Yes,
over the last 12 months MDXG made 3.06%, while its related Sector, the SPDR S&P Biotech (XBI) made -12.29%.
Over the last 3 months MDXG made -11.14%, while XBI made -13.61%.
Over the last 3 months MDXG made -11.14%, while XBI made -13.61%.
Performance Comparison MDXG vs Indeces and Sectors
MDXG vs. Indices MDXG is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 16.2% | -5.65% | 3.48% | -7.59% |
US NASDAQ 100 | QQQ | 16.0% | -9.20% | 3.27% | -8.58% |
US Dow Jones Industrial 30 | DIA | 15.8% | -1.83% | 3.77% | -4.65% |
German DAX 40 | DAX | 16.3% | -6.80% | -22.8% | -22.6% |
Shanghai Shenzhen CSI 300 | CSI 300 | 14.1% | -3.67% | 2.71% | -4.31% |
Hongkong Hang Seng | HSI | 13.1% | -11.8% | -4.88% | -10.6% |
India NIFTY 50 | INDA | 21.2% | 3.32% | 3.04% | 3.27% |
Brasil Bovespa | EWZ | 15.2% | -9.08% | -5.22% | 11.4% |
MDXG vs. Sectors MDXG is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 15.6% | -5.25% | -3.58% | -18.5% |
Consumer Discretionary | XLY | 15.9% | -6.07% | 4.46% | -11.2% |
Consumer Staples | XLP | 17.1% | 1.57% | -3.45% | -6.06% |
Energy | XLE | 16.4% | 1.40% | 10.1% | 12.5% |
Financial | XLF | 15.1% | -5.36% | -3.62% | -19.4% |
Health Care | XLV | 19.2% | 7.29% | 8.47% | 7.12% |
Industrial | XLI | 14.5% | -8.66% | 2.05% | -7.93% |
Materials | XLB | 16.4% | -5.40% | 8.37% | 8.29% |
Real Estate | XLRE | 17.6% | -3.38% | 2.73% | -12.4% |
Technology | XLK | 15.2% | -13.1% | 6.36% | -4.04% |
Utilities | XLU | 16.2% | -1.43% | -4.18% | -14.4% |
Aerospace & Defense | XAR | 14.3% | -13.0% | -8.02% | -24.3% |
Biotech | XBI | 22.8% | -3.65% | 23.6% | 15.4% |
Homebuilder | XHB | 15.8% | -3.32% | 16.7% | 10.6% |
Retail | XRT | 14.3% | -6.49% | 7.72% | 4.54% |